Genetics of treatment outcomes in major depressive disorder: present and future
Chiara Fabbri 1, Alessandro Serretti 2*
1Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, United Kingdom, 2Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
Received: August 22, 2019; Accepted: September 3, 2019; Published online: September 3, 2019.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant prescription. More than ten antidepressants (including tricyclics, selective serotonin reuptake inhibitors and venlafaxine) have already genetic biomarkers of response/side effects in clinical guidelines and drug labels. These are represented by functional genetic variants in genes coding for cytochrome enzymes (CYP2D6 and CYP2C19). Depending on the predicted metabolic activity, guidelines provide recommendations on drug choice and dosing. Despite not conclusive, the current evidence suggests that testing can be useful in patients who did not respond or tolerate at least one previous pharmacotherapy. However, the current recommendations are based on pharmacokinetic genes only (CYP450 enzymes), while pharmacodynamic genes (modulating antidepressant mechanisms of action in the brain) are still being studied because of their greater complexity. This may be captured by polygenic risk scores, which reflect the cumulative contribution of many genetic variants to a trait, and they may provide future clinical applications of pharmacogenetics. A more extensive use of genotyping in clinical practice may lead to improvement in treatment outcomes thanks to personalized treatments, but possible ethnical issues and disparities should be taken into account and prevented.
Keywords: antidepressant, major depressive disorder, genetics, gene, genome-wide association study, polygenic risk score, precision psychiatry